PT1596880E - Métodos e composições para suprimir a diferenciação de fibrócitos - Google Patents

Métodos e composições para suprimir a diferenciação de fibrócitos Download PDF

Info

Publication number
PT1596880E
PT1596880E PT03814319T PT03814319T PT1596880E PT 1596880 E PT1596880 E PT 1596880E PT 03814319 T PT03814319 T PT 03814319T PT 03814319 T PT03814319 T PT 03814319T PT 1596880 E PT1596880 E PT 1596880E
Authority
PT
Portugal
Prior art keywords
compositions
methods
fibrocyte differentiation
wound
suppressing
Prior art date
Application number
PT03814319T
Other languages
English (en)
Inventor
Richard Gomer
Darrell Pilling
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of PT1596880E publication Critical patent/PT1596880E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
PT03814319T 2002-12-23 2003-12-22 Métodos e composições para suprimir a diferenciação de fibrócitos PT1596880E (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43604602P 2002-12-23 2002-12-23
US43602702P 2002-12-23 2002-12-23
US51577603P 2003-10-30 2003-10-30
US51946703P 2003-11-12 2003-11-12
US52517503P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
PT1596880E true PT1596880E (pt) 2011-06-06

Family

ID=32686361

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03814319T PT1596880E (pt) 2002-12-23 2003-12-22 Métodos e composições para suprimir a diferenciação de fibrócitos

Country Status (13)

Country Link
US (3) US7935682B2 (pt)
EP (3) EP1576368B1 (pt)
JP (4) JP4922560B2 (pt)
AT (2) ATE500839T1 (pt)
AU (2) AU2003299873A1 (pt)
CA (2) CA2509241C (pt)
CY (1) CY1111536T1 (pt)
DE (2) DE60326273D1 (pt)
DK (1) DK1596880T3 (pt)
ES (1) ES2318195T3 (pt)
IL (1) IL169258A0 (pt)
PT (1) PT1596880E (pt)
WO (2) WO2004059318A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
WO2004059318A2 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
WO2007094776A1 (en) * 2006-02-15 2007-08-23 William Marsh Rice University Compositions and methods for suppressing fibrocyte differentiation
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US8642307B2 (en) * 2006-05-25 2014-02-04 Nalge Nunc International Corporation Cell culture surface chemistries
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2100140B1 (en) * 2006-11-30 2015-05-06 University Of Virginia Patent Foundation Methods for diagnosing fibrotic lung diseases
EP2094289B1 (en) * 2006-12-04 2013-03-13 Promedior, Inc. Combination of sap and enalapril for use in the treatment of fibrotic or fibroproliferative disorders
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
JP2012511929A (ja) * 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン 攪拌タンク反応器及び方法
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
JP5980508B2 (ja) 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
AU2010232591A1 (en) * 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
PL2987803T3 (pl) * 2009-06-17 2019-04-30 Promedior Inc Warianty SAP i ich zastosowanie
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
EP2571903B1 (en) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
WO2013090524A1 (en) * 2011-12-14 2013-06-20 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap)
WO2013096847A1 (en) * 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP6104286B2 (ja) * 2013-01-21 2017-03-29 三菱電機株式会社 電気機器識別システム、電気機器、及び、電気機器識別方法
US10562974B2 (en) 2013-03-13 2020-02-18 University Of Kentucky Research Foundation Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
BR112018016004A2 (pt) * 2016-02-08 2018-12-18 Univ Hackensack Medical Center composições e métodos para tratar feridas crônicas
JP6780600B2 (ja) * 2017-07-28 2020-11-04 株式会社デンソー 内燃機関制御システム

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) 1976-11-11 1980-03-05 Lock P M Wound dressing materials
DE2725261C2 (de) 1977-06-03 1986-10-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
DE3880647T2 (de) 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5092876A (en) 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5804446A (en) 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US6054121A (en) 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
CA2247388C (en) 1996-01-25 2009-06-02 Sven-Erik Svehag Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6365570B1 (en) 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
US20020058284A1 (en) 1998-02-17 2002-05-16 Jan G.J. Van De Winkel Methods and compositions for treating macrophage-mediated diseases
CN1235559C (zh) * 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
JPH11319542A (ja) * 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6600019B2 (en) 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (en) * 2000-03-30 2003-01-02 Brennen Medical Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002098278A2 (en) * 2001-06-04 2002-12-12 Cytokine Pharmasciences, Inc Peripheral blood fibrocytes differentiation pathway and migration to wound sites
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2004059318A2 (en) * 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2005258336A1 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)

Also Published As

Publication number Publication date
AU2003300266A2 (en) 2008-02-21
EP1576368A2 (en) 2005-09-21
CA2509241A1 (en) 2004-07-15
WO2004058292A2 (en) 2004-07-15
ATE422943T1 (de) 2009-03-15
JP4922560B2 (ja) 2012-04-25
JP2006511586A (ja) 2006-04-06
DK1596880T3 (da) 2011-06-14
AU2003299873A1 (en) 2004-07-22
AU2003300266B2 (en) 2009-10-08
WO2004058292A3 (en) 2004-10-28
EP1596880A2 (en) 2005-11-23
EP2017617A1 (en) 2009-01-21
JP2014141512A (ja) 2014-08-07
US8187599B2 (en) 2012-05-29
DE60326273D1 (de) 2009-04-02
CA2509241C (en) 2013-07-30
US20110311554A1 (en) 2011-12-22
JP2006514654A (ja) 2006-05-11
JP2011016824A (ja) 2011-01-27
EP1596880B1 (en) 2011-03-09
US20060002938A1 (en) 2006-01-05
ATE500839T1 (de) 2011-03-15
CY1111536T1 (el) 2015-10-07
WO2004059318A2 (en) 2004-07-15
DE60336347D1 (de) 2011-04-21
ES2318195T3 (es) 2009-05-01
WO2004058292A8 (en) 2005-08-25
IL169258A0 (en) 2007-07-04
AU2003300266A1 (en) 2004-07-22
WO2004059318A3 (en) 2005-05-06
EP1576368B1 (en) 2009-02-18
US20050238620A1 (en) 2005-10-27
AU2003299873A2 (en) 2008-02-28
JP4819364B2 (ja) 2011-11-24
CA2509392A1 (en) 2004-07-15
US7935682B2 (en) 2011-05-03
US7666432B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
PT1596880E (pt) Métodos e composições para suprimir a diferenciação de fibrócitos
SI2298338T1 (sl) Laktoferinski sestavki in postopki za zdravljenjekožnih ran
EP2221052A3 (en) Compositions for modulation of inflammation
WO2005046618A3 (en) Methods of treating eczema
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2008019129A3 (en) Solid dressing for treating wounded tissue
PT1365762E (pt) Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
GB0001449D0 (en) Compositions
WO2005044807A3 (en) Benzoimidazole compounds
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2003301761A1 (en) Method for treating wounds to promote healing
PL345452A1 (en) Chemotaxis-inhibiting protein of staphylococcus
WO2005094840A8 (en) Compositions comprising mannose phosphate for vaginal treatment
WO2002055096A8 (de) Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen
AU2003290970A1 (en) Compositions and method for treating affective, painful or allergic disorders
IL183117A0 (en) Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations
WO2006015183A3 (en) Pharmaceutical compositions for treating disorders of the skin
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing
WO2001085983A3 (en) Methods for testing compounds useful for treating diabetic complications
WO2003068224A3 (de) Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen
WO2007021900A3 (en) Compositions and methods for treating wounds
AUPS143302A0 (en) Treatment and composition for wound healing
AUPR563701A0 (en) Treatment and composition for wound healing
UA33545A (uk) Спосіб лікування дакріоциститу